Skip to main content
. Author manuscript; available in PMC: 2022 Dec 1.
Published in final edited form as: Biomaterials. 2021 Oct 13;279:121184. doi: 10.1016/j.biomaterials.2021.121184

Figure 4: ANCs targeted to immune checkpoints increases retention in tumor injection site and accumulation in TdLNs.

Figure 4:

ANC-formulated aPD1, aCTLA4, or isotype mAb (10μg) were injected i.t. into mice bearing d5 B16F10 tumors. NPs were labeled with AlexaFluor647, mAb with AlexaFluor700. A) AlexaFluor647 levels in tumors from aPD1-, aCTLA4-, or isotype-ANCs over 72 h. B) Cumulative area under the curve (AUC) of AlexaFluor647 signal over 72 h post injection, quantified from A. C) AlexaFluor647 levels in TdLNs from aPD1-, aCTLA4-, or isotype-ANCs over 72 h. D) Cumulative AUC of AlexaFluor647 signal over 72 h post injection, quantified from C. Statistical analyses were done using two- (A, C) or one-way (B, D) ANOVA with Tukey’s test. * p<0.05, ** p<0.01, *** p<0.001.